Engineering Immune Organoids to Study Pediatric Cancer

Summary

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

Eligibility

Inclusion Criteria:

* Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
* Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
* Brain tumors
* Renal tumors
* Neuroblastoma
* Sarcomas
* Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
* Affiliated to a social security system or beneficiary of the same.

Exclusion Criteria:

* Any histology not mentioned in the inclusion criteria
* Adult patient or parents/guardians incapable/incapable of giving its/their consent
* Patients deprived of their liberty by a judicial or administrative decision

Conditions5

Interventions1

Related trials

• Angiogenic Biomarkers in Juvenile Idiopathic Arthritis — Assistance Publique - Hôpitaux de Paris
• Basal Plasma Lithium Levels and Suicidal Events — University Hospital, Montpellier
• Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects — Institut National de la Santé Et de la Recherche Médicale, France
• Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia — Centre Hospitalier Universitaire, Amiens
• Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas — Assistance Publique Hopitaux De Marseille
• Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial — Centre Hospitalier Universitaire, Amiens
• Creation of a French South-Eastern Database and DNA-bank of Congenital Heart Disease to Explore the Genetic Pathways — Assistance Publique Hopitaux De Marseille
• Detection of ISUP≥2 Prostate Cancers Using Multiparametric MRI: Prospective Multicenter Comparison of the PI-RADS Score and an Artificial Intelligence System — Hospices Civils de Lyon

Browse More Trials